mRNA vaccines in gastric cancer: How close are we?

Gastric cancer (GC) is one of the neoplasms with higher mortality, causing around 700 000 deaths worldwide. Despite efforts in GC research, chemotherapy, radiotherapy, and conventional surgery have not been sufficiently effective. Immunotherapy has been proposed as an alternative, and the most recent guidelines recommend its use as a third-line treatment for advanced GC. In this context, the development of an mRNA vaccine to control GC is presented as a promising alternative, either to stimulate an immune response against tumor cells or as a therapeutic option to restore the immune system and reduce mortality from GC. Although there is still a long way to go, technological advances and ongoing research bring us closer to the development of an mRNA vaccine for GC that can be administered in combination with immune checkpoint inhibitors.